Tue.Sep 10, 2024

article thumbnail

Community Pharmacist Education to Combat Vaccine Hesitancy

Drug Topics

Researchers explored an alternative pharmacist education intervention as a way of improving pharmacist-patient conversations and decreasing vaccine hesitancy among patients.

Vaccines 201
article thumbnail

Patients With Difficult-To-Treat Asthma Require Different Intervention Methods Based on Comorbidities

Pharmacy Times

To help with treatment response and compliance as well as optimize treatment, communication between patients and health care providers is necessary.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Education Is Crucial to Close Gaps in Colorectal Cancer Risk Awareness

Drug Topics

The #MyCRChistory campaign encourages the public to share their family history of colorectal cancer.

191
191
article thumbnail

Half of women skip or delay care due to 'triple threat' of factors, report finds

Fierce Healthcare

Half of women in the U.S. skip or delay medical care due to the “triple threat” of affordability, access challenges and past negative experiences, a new Deloitte report finds. | The Deloitte report, based on a survey of more than 2,000 consumers, found that 50% of women report skipping or delaying medical care and are 35% more likely to skip care than men.

138
138
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Semaglutide Therapy Associated With Fewer COVID-19–Related Deaths

Drug Topics

Data from the SELECT clinical trial were analyzed to evaluate the role of semaglutide therapy on all-cause, cardiovascular, and non-cardiovascular mortality during the COVID-19 pandemic.

112
112
article thumbnail

STAT+: Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries

STAT

Amid calls to expand access to medicines in low- and middle-income countries, a new analysis finds that most of the world’s 20 largest pharmaceutical companies have taken steps to reach patients, but many efforts are yielding decidedly mixed results. On the one hand, 19 companies have established methods for providing treatments to these countries — but only nine of the drugmakers created comprehensive plans.

More Trending

article thumbnail

STAT+: Novo Nordisk’s amylin pill leads to substantial weight loss in early study

STAT

Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates that may be more effective than Wegovy. In a Phase 1 trial, a 50-mg dose of the daily pill called amycretin, which activates receptors of both the amylin and GLP-1 hormones, led to 10.4% weight loss at about three months after the start of treatment.

139
139
article thumbnail

After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned

Fierce Pharma

After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. | Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics.

125
125
article thumbnail

AI threatens to cement racial bias in clinical algorithms. Could it also chart a path forward?

STAT

PROVIDENCE, R.I. — In a cavernous converted chapel at Brown University, physician and data scientist Leo Celi observed from the sidelines as a tableful of high school students passed around a plastic, crocodilian device. The pulse oximeter clamped down on one student’s fingertip: Ninety-seven, he read out loud, before handing it off to the student next to him.

133
133
article thumbnail

IVIG Associated With Shorter Hospital, ICU Length of Stay in Immunocompromised Patients With Respiratory Infections

Pharmacy Times

When IVIG was administered within 48 hours of hospital admission, hospital and ICU length of stay were dramatically shortened.

Hospitals 132
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Obesity drug worked in children ages 6 to 12, study says, raising hopes and concerns

STAT

The first late-stage trial of a GLP-1 drug in young children with obesity showed the treatment helped lower body mass index. But the findings also raise questions about whether obesity medications, some of which are currently approved for teenagers, should also be given to children at such a young age. The 56-week trial tested Novo Nordisk’s Saxenda, the predecessor of Wegovy, coupled with lifestyle interventions in children ages 6 to 12.

127
127
article thumbnail

Depemokimab Shown to Reduce Severe Asthma Exacerbations in Phase 3 Trials

Drug Topics

Data from the SWIFT-1 and SWIFT-2 studies were presented by GSK at the European Respiratory Society International Conference.

112
112
article thumbnail

STAT+: Former Verily executives hatch plan to invest millions in high-tech medical data

STAT

Two former Verily executives say that they are starting a new initiative, Highlander Health, to push forward an effort decades in the making: making it so that the records collected in hospitals can be used in real-time to advance science, decreasing the cost of conducting clinical trials and speeding medical progress while helping patients get the right drug for them.

Hospitals 119
article thumbnail

Life sciences real estate is booming amid looming ‘patent cliff’, but what lies ahead?

pharmaphorum

Investment in life sciences real estate is booming as the industry faces the looming 'patent cliff' Learn about the current trends and what lies ahead for this sector.

106
106
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Roivant acquires drug for pulmonary hypertension from Bayer

STAT

For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the next drug it planned to buy with some of the $6 billion made from last year’s Roche deal. On Tuesday, Gline obliged. Roivant has acquired from Bayer, the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a family of serious lung diseases in which high blood pressure affects the arteries in the lungs

122
122
article thumbnail

Does the flu shot make you tired?

The Checkup by Singlecare

An estimated 8% of Americans get the flu each year, according to the Centers for Disease Control and Prevention (CDC). If you’ve ever been suddenly sidelined by influenza, you’ve experienced the misery of being completely drained—too weak to even get out of bed. As you wait for the debilitating flu infection to run its course, you’d do anything to speed up the process.

Vaccines 105
article thumbnail

Q&A: Atsena Therapeutics’ gene therapy for inherited blindness shows promise

STAT

Seven years after the FDA approved Luxterna , scientists have yet to bring another congenital blindness treatment to the market. A team of researchers from the Perelman School of Medicine at the University of Pennsylvania aims to change this. The group recently published a study in The Lancet documenting their success using gene therapy to treat an inherited retinal blindness that affects as many as 100,000 people globally.

article thumbnail

Behind the Scenes of CAR T-Cell Therapy: The Role of the Pharmacist

Pharmacy Times

Breanne Peyton-Thomas, PharmD, BCOP, discusses her work as a pharmacist at Ochsner Health on the CAR T-cell therapy team.

123
123
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Opinion: How much does it cost to give birth in the U.S.?

STAT

What does it cost to have a baby in the United States? This question has always vexed me. I’ve tried unsuccessfully to prospectively price deliveries for family and friends over the years. After insurance, deliveries can range from a few hundred dollars to a couple of thousand. If you’re underinsured or have a more complex birth, it can cost more than $10,000 out of pocket.

Insurance 113
article thumbnail

Habitat Health secures $50M, plans to open first PACE center with Kaiser Permanente next year

Fierce Healthcare

Habitat Health, an organization founded last year to provide care support to older adults at home, secured $50 million in capital from investors Town Hall Ventures, New Enterprise Associates and Ka | Habitat Health, an organization founded last year to provide care support to older adults at home, secured $50 million in capital from investors Town Hall Ventures, New Enterprise Associates and Kaiser Permanente.

117
117
article thumbnail

The little-known bill that made drugs more affordable

STAT

This is Part 4 of “ Behind the Counter ,” an in-depth video series demystifying the complex world of patents and drug pricing. Years ago, when a brand-name medication’s patent expired, consumers had to wait a long time for a more affordable generic version to come to market. But in 1984, a little-known law put an end to that waiting period and paved the way for the large quantity of generic drugs available today.

114
114
article thumbnail

GSK’s Depemokimab Significantly Reduces Asthma Exacerbations

Pharmaceutical Commerce

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.

105
105
article thumbnail

Key lawmakers are wary of giving FDA more cash to crack down on e-cigs

STAT

WASHINGTON – Powerful House lawmakers from both parties are skeptical of the Food and Drug Administration’s pitch to start collecting fees from e-cigarette companies, similar to how the agency assesses them on tobacco firms. FDA officials say that the fees, which e-cigarette companies would pay when filing applications with the agency, would give regulators resources to tackle the thousands of illegal vapes lining store shelves.

FDA 111
article thumbnail

A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

PharmaVoice

Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

article thumbnail

STAT+: Elevance buys IU Health’s insurance company

STAT

Elevance Health, the parent of more than a dozen state Blue Cross Blue Shield plans, is purchasing Indiana University Health’s insurance business in a deal that would increase its dominance in several key cities in the state. IU Health’s decision to sell is the latest and most prominent example of hospital systems giving up on the idea that they can be both a provider and payer of care.

Insurance 105
article thumbnail

Creyon Bio secures second patent for AI-powered oligonucleotide engineering

Outsourcing Pharma

Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent.

99
article thumbnail

Health care AI investment hype, and value-based-care model for mental health apps

STAT

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Flare Capital ‘s new examination of 4,000 healthcare AI venture capital deals looked at where investment has actually created value — that is, what early-stage, venture-backed technology matures enough to impact the health care ecosystem?

108
108
article thumbnail

Teva agrees to pay Baltimore City $80m for fuelling opioid epidemic

Pharmaceutical Technology

Baltimore opted out of a national settlement last year, instead pursuing its own claim against the opioid manufacturer.

105
105
article thumbnail

STAT+: After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives

STAT

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on Wednesday, bringing the firms closer to securing Food and Drug Administration approval after the agency rejected their application last year. In the Phase 3 trial, dubbed Liberty-Cupid Study C, patients took antihistamines, the current standard of care, and Dupixent or a placebo.

FDA 102
article thumbnail

Enhance Your Pharmacy’s Efficiency with ER Prescription Management

PioneerRx

ER prescriptions requires a different kind urgency and attention to detail compared to maintenance medications — so let’s get on the right foot.

article thumbnail

Morning Rounds: Apple Watch takes on sleep apnea and tonight’s presidential debate

STAT

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Hello, happy Tuesday. Temperatures are projected to be in the 50s every morning this week in Boston, per a glance at my phone. Is it officially fall? Where can I get a good apple cider donut? What stories should we report before the end of the year creeps up on us?

101
101
article thumbnail

It’s the Business Model, Stupid.

Pharmacy Times

Blaming community pharmacies and community pharmacists for a lack of expedited practice evolution is naive at best, and disingenuous or outright malicious at worst.

article thumbnail

Five biotech news stories you need to read today

STAT

Morning! Today, we’ll keep riding the bispecific wave, and tell you what Verily and FDA alum Amy Abernethy is up to next. Oh, and a programming note: The annual ESMO meeting opens this weekend, and we’ve got a pop-up newsletter. Sign up if you’re interested. The need-to-know this morning Roivant Sciences acquired from Bayer , the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a

FDA 98